Suboxone lawsuit: who can file and what happens next

Who may qualify?

If you used Suboxone film that melts in your mouth and then had tooth damage, ask a lawyer about a claim. The federal cases concern tooth decay and damage said to be linked to that film. This guide does not decide whether you qualify. [3]

Start with the exact drug and form you took. Bring the label or a list from the pharmacy, rather than guessing from a box color. Note when you began and stopped using each form. Add the dates when a dentist found decay, infection or lost teeth. If you do not recall an exact date, say so and ask the pharmacy for its records. [5] [1]

Taking treatment for opioid use does not mean you did something wrong. Your care and the claim are separate questions. Ask the lawyer which records matter, what the law requires and whether the firm is taking film cases. We have not verified a minimum number of teeth, dose or years of use for this intake. Do not treat a checklist from an ad as a legal rule.

What could I get?

No one has announced a dental claim payment in the July 2026 provider order reviewed here. A lawsuit may ask for money for harm, but asking is not winning. Have a lawyer check any offer that names a sum. [4] [6]

Make a folder for dental bills, estimates and care records. Write down missed work and any changes you want the lawyer to understand. Label what you paid and what is only an estimate. These are useful topics for a claim discussion, not a formula for the value of your case. Do not buy a treatment plan on the strength of a predicted award.

Ask what would be deducted if money were recovered. The lawyer’s agreed fee and case expenses are separate issues. Ask whether bills or other repayment claims need review too. We have not checked any private offer, proposed payment schedule or fee terms for this intake. No payout range or payment date is promised. [7]

Is there a deadline?

A personal deadline depends on the law and the facts of your tooth-damage claim. The FDA warning date is not a universal filing deadline. Ask a lawyer to work out which dates matter to you. [8] [1]

Write down when you took the film, first had symptoms, received dental care and learned of a possible link. If you have a letter from a lawyer or court, keep it with those notes. Tell the lawyer about any earlier claim, agreement or dismissal. Ask for the deadline and the reason for it in writing. Do not change a date to fit a rule you saw online.

Court orders can also set tasks for people who already have a case. The provider order governs evidence gathering; it does not replace your personal filing rule. If an old date appears on a website, ask what that date was for. A missed case-management task and the right to start a new claim are different questions to review. [4] [8]

What happens after I check?

A case check starts with questions; it does not file a lawsuit. If you hire a lawyer, ask which court papers would be needed and who will file them. A federal lawsuit starts when papers are filed with the court, rather than when you fill in a website form. [6]

First, identify the firm that receives your answers. Next, ask whether it will review your film use and dental history, and whether it can represent you. Then read its terms before you agree to hire it. We have not confirmed the form’s recipients, response time or acceptance rules. Do not assume a message or a call means a case was filed.

Ask for copies of anything you sign and a way to contact the person handling your file. If you help a family member, ask what authority or permission is needed. HHS limits record access to the patient or a proper personal representative. A relative can help make a list without assuming the right to sign legal or medical releases. [5]

Questions people ask

The questions below address film use, dental records and safe care while considering a claim. They cover safe care and ways to prepare for a case review. They do not replace a dentist’s care plan or an individual legal review.

How Suboxone Film Causes Severe Tooth Decay

Suboxone sublingual film delivers buprenorphine and naloxone through the oral mucosa, requiring the film to dissolve slowly under the tongue or between the cheek and gum. This mechanism of delivery exposes teeth and enamel to an acidic, dry oral environment for extended periods — conditions that systematically destroy dental enamel and cause severe, irreversible tooth decay even in patients who had no prior dental problems.

Citric Acid Directly Lowers Oral pH

Suboxone sublingual film contains citric acid as a buffering excipient to stabilize the film formulation. When the film dissolves under the tongue, citric acid is released directly into saliva, driving oral pH sharply below 5.5 — the critical threshold at which hydroxyapatite, the mineral matrix of dental enamel, begins to dissolve. Prolonged periods below this pH threshold cause progressive, irreversible enamel demineralization. Because the film must dissolve slowly over 5 to 10 minutes per dose, acidic conditions persist around teeth for extended periods multiple times per day, every day of treatment.

Buprenorphine Causes Profound Xerostomia (Dry Mouth)

Buprenorphine, a partial mu-opioid receptor agonist, produces significant xerostomia — pathological dry mouth — as a direct pharmacological effect. Saliva is the primary physiological defense against oral acid: it neutralizes pH, buffers against enamel demineralization, remineralizes early enamel lesions, and mechanically washes away acids and bacteria. When buprenorphine suppresses salivary flow, this multi-layered protective system is compromised. The absence of adequate saliva means oral pH cannot recover between doses, acid accumulates against tooth surfaces, and remineralization cannot keep pace with demineralization. Dry mouth from buprenorphine is dose-dependent, persistent throughout daily treatment, and not readily reversible during treatment.

Buprenorphine's Direct Enamel Demineralization

Beyond its indirect effects through xerostomia, buprenorphine has been shown in laboratory studies to directly interact with enamel mineral structure. Buprenorphine is weakly acidic (pKa approximately 8.2) and when dissolved in saliva contributes to the acidic microenvironment at the tooth surface. At the sublingual delivery site, concentrated buprenorphine solution contacts the lingual surfaces of lower front teeth and the undersurface of the tongue, where enamel demineralization has been consistently documented in affected patients. The cumulative direct chemical contact between buprenorphine and enamel over months and years of daily dosing accelerates enamel loss beyond what would be predicted from pH alone.

Prolonged Sublingual Contact Time Amplifies Damage

Suboxone film is specifically formulated for slow sublingual dissolution to maximize buprenorphine bioavailability through the oral mucosa. Patients are instructed to hold the film under the tongue without swallowing until it fully dissolves — a process that takes 5 to 10 minutes per dose. With typical dosing of 1 to 4 films per day, patients spend 10 to 40 minutes daily with an acid-releasing, moisture-absorbing film in direct contact with or adjacent to tooth surfaces. Over months and years of daily treatment, this represents an extreme cumulative acid exposure unlike any other FDA-approved drug delivery mechanism. The lingual surfaces of mandibular incisors and the palatal surfaces of maxillary teeth are particularly vulnerable due to their proximity to the sublingual dissolution site.

Neglected Dental Care During Addiction Treatment

Patients receiving medication-assisted treatment (MAT) for opioid use disorder are among the most medically underserved populations in the United States. Many enter treatment with pre-existing dental disease exacerbated by years of opioid use, nutritional neglect, and lack of dental insurance. MAT programs historically focused on addiction stabilization with minimal integration of dental health monitoring. Patients were not warned that Suboxone itself — independent of prior drug use — could cause or dramatically accelerate dental disease. Without warnings, neither patients nor prescribers monitored for drug-induced dental injury, and early enamel demineralization went undetected and untreated until patients presented with advanced decay, abscesses, cracked teeth, and complete tooth loss.

• High Dosage Frequency and Long Treatment Duration: Buprenorphine/naloxone is a long-term maintenance medication. Clinical guidelines recommend treatment durations of one to several years, and many patients take Suboxone for 5 to 10 years or longer. The dental injury risk is cumulative and time-dependent — the longer the treatment, the greater the acid exposure and the more severe the enamel destruction. Patients taking multiple films per day (up to 24 mg/day) face proportionally greater daily acid loading than those on lower doses.
• No Prior Dental Warning for Two Decades: Suboxone sublingual film was approved by the FDA in 2002 — and for nearly 20 years, neither the drug label, prescriber information, nor patient medication guides contained any warning about dental problems. Indivior's failure to warn meant that millions of patients took Suboxone for years without any knowledge that the drug was destroying their teeth, and without taking protective measures such as rinsing with water after each dose, using fluoride supplements, or increasing dental monitoring.
• Population Vulnerability — Addiction Treatment Context: The population prescribed Suboxone is disproportionately affected by poverty, lack of dental insurance, prior oral health neglect, and reduced access to dental care. These pre-existing vulnerabilities mean that drug-induced dental damage has no counterbalancing protection from routine professional dental care or timely intervention. Opioid use disorder also independently contributes to dry mouth (from prior opioid use), poor nutrition, and neglect of preventive dental care — creating a population particularly susceptible to the additive dental harms of Suboxone itself.
• Irreversibility of Enamel Loss: Dental enamel is the hardest substance in the human body and, critically, it cannot regenerate. Once dissolved by acid demineralization, enamel does not grow back. Early enamel damage can be partially arrested by fluoride and remineralization agents, but moderate to severe enamel loss requires restorative intervention — fillings, crowns, root canals, extractions, and dental implants or dentures. Many Suboxone patients have experienced near-complete or complete loss of multiple teeth, requiring full-mouth reconstruction.
• The FDA added a Boxed Warning — its most serious warning — to all buprenorphine-containing sublingual and buccal medications in January 2022, explicitly warning of severe dental problems including tooth decay, cavities, oral infections, and tooth loss.
• The FDA's January 2022 safety communication confirmed it had received reports of serious dental problems in patients taking buprenorphine products dissolved in the mouth, including patients with no prior history of dental disease.
• Peer-reviewed case series published in medical literature have documented severe buprenorphine-associated dental injury, with multiple patients losing the majority of their teeth after years of sublingual buprenorphine film use.
• The mechanism of injury — citric acid-mediated pH reduction combined with buprenorphine-induced xerostomia — is supported by in vitro enamel dissolution studies and is biologically plausible based on established oral chemistry.

Patients who took Suboxone sublingual film (buprenorphine/naloxone) for opioid use disorder treatment and suffered severe tooth decay, multiple cavities, cracked teeth, abscesses, or tooth loss may have viable legal claims against Indivior PLC. The harm mechanism is drug-specific, well-documented in FDA records and peer-reviewed literature, and distinct from any pre-existing dental condition. The absence of dental warnings for nearly 20 years — from FDA approval in 2002 through the January 2022 Boxed Warning — is central to plaintiffs' failure-to-warn claims. Indivior knew or should have known of the dental injury risk through its own pharmacological research and through adverse event reports submitted to the FDA, yet failed to warn prescribers and patients until the FDA compelled the label change.

Multiple Tooth Extractions and Implant Need

When dental erosion and caries progress beyond the point of restoration, tooth extraction becomes necessary. Suboxone-associated dental damage frequently results in the loss of multiple teeth — sometimes an entire arch — requiring complex and costly rehabilitation. Dental implants, the gold standard replacement for natural teeth, require osseointegration (fusion with jawbone), involve multiple surgeries over 3 to 9 months. Where bone loss has occurred following extraction, bone grafting procedures add cost and extend the treatment timeline.

• Tooth loss (single or multiple teeth)
• Jawbone resorption following extraction
• Difficulty chewing, leading to nutritional compromise
• Aesthetic impact — gaps, sunken facial appearance
• Pain and healing complications following extraction surgery
• Extent of Suboxone-related decay (the more teeth affected, the more likely extractions are needed)
• Delayed diagnosis (the longer the damage goes untreated, the less salvageable teeth become)
• Bone loss following untreated extraction sites
• Systemic health factors that complicate implant osseointegration (smoking, diabetes)
• Tooth extraction (simple or surgical, depending on root anatomy)
• Socket preservation and bone grafting to maintain ridge volume
• Dental implant placement (titanium post surgically placed in jawbone)
• Implant restoration with crown, bridge, or implant-supported denture
• Interim prosthetics (removable partial or full dentures) during implant healing period
• All-on-4 or All-on-6 full-arch implant-supported prosthesis for total tooth loss

Indivior PLC — spun off from Reckitt Benckiser Pharmaceuticals in 2014 — built a multi-billion-dollar business on Suboxone, dominating the U.S. medication-assisted treatment market for opioid use disorder.

A Pattern of Prioritizing Profit Over Patient Safety

The Suboxone dental injury litigation sits at the intersection of two of the most significant public health crises of the 21st century: the opioid epidemic and the erosion of trust in pharmaceutical manufacturers. Patients who took Suboxone were, by definition, in recovery from opioid addiction — a vulnerable population deserving of the highest duty of care. Instead, Indivior and its predecessor Reckitt Benckiser profited from a medication they fraudulently marketed, suppressed generic competition to maintain pricing power, and failed to warn of a serious, preventable dental injury for nearly 20 years. The dental injury victims are not abstract plaintiffs — they are people who trusted medication-assisted treatment to help them rebuild their lives, only to lose their teeth in the process.

• In 2019, federal prosecutors described Indivior's Suboxone marketing scheme as a plan to 'hook patients on the highest dose of Suboxone Film by using false safety claims' — language that appears in the criminal information filed against the company.
• The FTC's investigation found that Reckitt's withdrawal of the Suboxone tablet and launch of the film was coordinated specifically to block generic competition, delaying patient access to affordable alternatives by years and locking patients into the brand-name film formulation that causes dental injury.
• Despite accumulating FAERS dental adverse event reports beginning well before 2015, Indivior did not voluntarily update its label to warn of dental problems — the FDA compelled the 2022 Boxed Warning after conducting its own signal review and determining the risk was serious and not adequately characterized.
• Indivior CEO Shaun Thaxter was convicted of a federal misdemeanor charge in 2020 related to the Suboxone marketing fraud — a rare instance of pharmaceutical executive criminal accountability — further establishing the corporate culture of misconduct at the highest levels of the company.

Patients who suffered severe dental injury have strong legal claims grounded in the FDA's own findings and Indivior's documented history of misconduct.

Suboxone Dental Injury Lawsuit Filing Deadlines

Suboxone dental injury claims are governed by each state's product liability or personal injury statute of limitations, typically 2 to 3 years from the date of injury or — critically — from the date the plaintiff discovered, or reasonably should have discovered, that Suboxone caused their dental injuries. On January 12, 2022, the FDA warned about dental problems with buprenorphine medicines dissolved in the mouth, and some lawyers argue that warning affects when the deadline starts for patients who had no earlier reason to connect their dental damage to their medication.

The Discovery Rule and the January 2022 FDA Safety Communication

Most states apply a discovery rule to pharmaceutical product liability claims: the statute of limitations begins when the plaintiff knew or should have known that their injury was caused by the defendant's product. On January 12, 2022, the FDA warned about dental problems with buprenorphine medicines dissolved in the mouth and required a new warning in the prescribing information and patient Medication Guide. Many plaintiff attorneys argue that the 2- or 3-year SOL clock should begin running from January 12, 2022 for patients who had not previously connected their dental damage to Suboxone. However, some states apply different accrual rules, and some claims arising from damage that was diagnosed and attributed to Suboxone before 2022 may be time-barred. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.

A patient in Ohio began taking Suboxone film in 2017 and lost four teeth by 2020. She assumed poor oral health was to blame. After seeing news coverage of the FDA's January 2022 warning, she contacted an attorney in August 2022.

Ohio has a 2-year statute of limitations for product liability claims (ORC § 2305.10). If the court applies the discovery rule from the January 2022 FDA communication, she acted well within that 2-year period. However, if a court finds she had reason to know earlier (e.g., a dentist suggested Suboxone might be a factor before 2022), her claim could be at risk. Early consultation with an attorney was the right call.

A patient in West Virginia began Suboxone in 2015, noticed rapid decay by 2016, and lost six teeth by 2018. He did not file a claim until 2023.

West Virginia has a 2-year SOL for product liability (WV Code § 55-2-12). If his injury was reasonably discoverable by 2018, a court could start the clock then rather than at the 2022 FDA communication. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you. This illustrates why patients who notice unusual dental deterioration during Suboxone use may want to talk to a lawyer soon rather than waiting for government confirmation.

Some lawyers argue the January 12, 2022 FDA safety communication affects when the deadline starts under state discovery rules. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.